Seres Therapeutics MCRB
NASDAQ MCRB
$2.09 -0.04 (-1.88%)
At close: Oct 23, 2026 · 4:00 PM EDT

Seres Therapeutics (MCRB) Gains from Sales and Divestitures (2024 - 2025)

Updated

Seres Therapeutics' Gains from Sales and Divestitures was $192,000 in Q4 2025.

Analysis

Seres Therapeutics (MCRB) Gains from Sales and Divestitures (2024 - 2025) Analysis & Trends

  • In earlier years, Gains from Sales and Divestitures was $146.71 million in FY2024.
  • The Q4 2025 figure marks the highest quarterly Gains from Sales and Divestitures since Q3 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,199.50 Bn 1,168.08 Bn 19.71 Bn
2 Johnson & Johnson 635.17 Bn 555.03 Bn 17.30 Bn
3 AbbVie 504.69 Bn 477.85 Bn 12.70 Bn
4 Merck 358.43 Bn 312.86 Bn 12.21 Bn
5 Novartis Ag 288.36 Bn 252.75 Bn 11.24 Bn
6 Astrazeneca 265.78 Bn 239.54 Bn 12.86 Bn
7 Amgen 237.46 Bn 192.86 Bn 7.24 Bn
8 Gilead Sciences 193.65 Bn 167.76 Bn 6.22 Bn
9 Pfizer 171.05 Bn 118.00 Bn 10.94 Bn
10 Seres Therapeutics 20.54 Mn -118.29 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 192,000.00
Sep 30, 2024 147.00 Mn
Mar 31, 2024 -293,000.00
API Access

Seres Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=MCRB&period=max&api_key=YOUR_API_KEY